APA (7th ed.) Citation

Elliot, E. R., Polli, J. W., Patel, P., Garside, L., Grove, R., Barnett, V., . . . Wyk, J. v. (2024). Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials. Journal of Infectious Diseases, 230(1), e34. https://doi.org/10.1093/infdis/jiad580

Chicago Style (17th ed.) Citation

Elliot, Emilie R., et al. "Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials." Journal of Infectious Diseases 230, no. 1 (2024): e34. https://doi.org/10.1093/infdis/jiad580.

MLA (9th ed.) Citation

Elliot, Emilie R., et al. "Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials." Journal of Infectious Diseases, vol. 230, no. 1, 2024, p. e34, https://doi.org/10.1093/infdis/jiad580.